Why the study?
Whether beta-blockers remain efficacious in the post-reperfusion era is currently debated in light of recent controversial reports.
Does beta-blocker use improve short- and long-term mortality in patients hospitalized for acute coronary syndrome with LVEF ≥40%?
Population
Patients hospitalized for ACS with LVEF ≥ 40%
Comparison
BB use prior to admission, 24-hour post-admission, or on discharge vs non-use
Design
Multicenter cohort study
Follow-up
12 months
Authors
Loading...
BB use was associated with lower short-term mortality in preserved-EF ACS; leaves open long-term benefit and need for RCTs.
Does beta-blocker use improve short- and long-term mortality in patients hospitalized for acute coronary syndrome with LVEF ≥40%?
In patients with ACS and LVEF ≥40%, beta-blocker use is associated with improved in-hospital and 1-month mortality but has no significant impact on 6- or 12-month outcomes.
Khalil et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: